

Company Fact Sheet

Headquarters:

25841 Industrial Blvd. Suite 275
Hayward, CA 94545
USA
+1 650.239.9070

Number of Employees:

265+

RefleXion Medical:

A privately held therapeutic oncology company founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri to create a new cancer treatment through biological guidance for the treatment of localized and metastatic cancer.

Technology:

Granted Breakthrough Device Designation by the U.S. Food & Drug Administration (FDA) for lung tumors, the **RefleXion® X1 machine with SCINTIX™ biology-guided radiotherapy* (BgRT)** is the first to utilize the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are moving.

SCINTIX therapy uses positron emission tomography (PET) imaging with stereotactic radiotherapy to guide radiation to the real-time location of the tumor for treatment. SCINTIX technology is the first and only radiotherapy approach that uses a single radiotracer injection to transform cancer cells into real-time biological guides that steer radiotherapy delivery to the tumor.

The innovative technology may represent a significant advance in cancer treatment for patients by leveraging a proven modality for visualizing cancer with one of the most effective ways to treat cancer, thereby fundamentally altering the cancer treatment model.

Funding & Investors:

RefleXion has raised \$450M in debt and equity funding. The company is backed by Ascension Ventures, Catalio, PSP Investments, Ally Bridge Group, TPG Growth/The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders Pfizer Ventures, and Johnson & Johnson Innovation – JJDC, Inc. The company has also received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program.

Media Resources:

Todd Powell, president, CEO
Sam Mazin, Ph.D., founder, CTO
Martyn Webster, CFO
Sean Shirvani, M.D., CMO
Judy Bartlett-Roberto, vice president, marketing

Media Contact:

Amy Cook
acook@reflexion.com

Investor Contact:

Martyn Webster
martyn@reflexion.com

*The Reflexion® X1 is cleared for SBRT/SRS/IMRT treatments. SCINTIX™ biology-guided radiotherapy is limited by U.S. law to investigational use.